ABBV · Abbvie Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.00B | - | $15.78B | $15.42B | $13.34B | - | $14.46B | $14.46B | $12.31B | - |
| Cost of Revenue | $4.22B | - | $5.30B | $4.35B | $4.00B | - | $4.21B | $4.20B | $4.09B | - |
| Gross Profit | $10.78B | - | $10.47B | $11.08B | $9.34B | - | $10.25B | $10.26B | $8.22B | - |
| R&D | $2.47B | - | $2.32B | $2.13B | $2.07B | - | $2.13B | $1.95B | $1.94B | - |
| SG&A | $3.58B | - | $3.57B | $3.25B | $3.29B | - | $4.21B | $3.38B | $3.31B | - |
| Total Operating Expenses | $11.01B | - | $13.87B | $10.53B | $9.61B | - | $10.63B | $10.46B | $9.51B | - |
| D&A | $188.00M | - | $192.00M | $186.00M | $181.00M | - | $191.00M | $184.00M | $183.00M | - |
| Operating Income | $3.99B | - | $1.90B | $4.89B | $3.73B | - | $3.83B | $4.00B | $2.80B | - |
| Interest Expense | $717.00M | - | $739.00M | $740.00M | $700.00M | - | $720.00M | $726.00M | $660.00M | - |
| Income Tax | $342.00M | - | $526.00M | $613.00M | $372.00M | - | $520.00M | $773.00M | $383.00M | - |
| Net Income | $695.00M | - | $186.00M | $938.00M | $1.29B | - | $1.56B | $1.37B | $1.37B | - |
| EPS - Basic | $0.39 | - | $0.10 | $0.52 | $0.72 | - | $0.88 | $0.77 | $0.77 | - |
| EPS - Diluted | $0.39 | - | $0.10 | $0.52 | $0.72 | - | $0.88 | $0.77 | $0.77 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.39B | $5.23B | $5.63B | $6.47B | $5.17B | $5.52B | $7.26B | $13.13B | $18.07B | $12.81B |
| Accounts Receivable | $12.48B | $12.59B | $12.77B | $12.64B | $12.48B | $10.92B | $11.47B | $11.72B | $11.95B | $11.15B |
| Inventory | $5.05B | $4.95B | $4.94B | $4.96B | $4.53B | $4.18B | $4.45B | $4.22B | $4.25B | $4.10B |
| Accounts Payable | - | $3.59B | - | - | - | $2.94B | - | - | - | $3.69B |
| Current Assets | $33.53B | $29.06B | $28.54B | $29.26B | $27.68B | $25.58B | $27.79B | $33.82B | $38.87B | $33.00B |
| Total Assets | $136.46B | $133.96B | $133.90B | $137.18B | $136.16B | $135.16B | $143.42B | $141.94B | $148.87B | $134.71B |
| Current Liabilities | $42.10B | $43.29B | $39.39B | $39.77B | $36.40B | $38.75B | $43.06B | $41.91B | $41.52B | $37.84B |
| Long-term Debt | - | $64.50B | - | - | - | $66.84B | - | - | - | $59.24B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($6.66B) | ($3.27B) | ($2.64B) | ($183.00M) | $1.42B | $3.33B | $6.03B | $6.78B | $8.01B | $10.36B |
| Retained Earnings | ($17.87B) | ($15.49B) | ($14.23B) | ($11.50B) | ($9.53B) | ($7.90B) | ($4.96B) | ($3.77B) | ($2.38B) | ($1.00B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.83B | - | - | - | $1.64B | - | - | - | $4.04B | - |
| Investing Cash Flow | ($574.00M) | - | - | - | ($735.00M) | - | - | - | ($9.59B) | - |
| Financing Cash Flow | $919.00M | - | - | - | ($1.26B) | - | - | - | $10.82B | - |
| CapEx | $265.00M | - | - | - | $235.00M | - | - | - | $193.00M | - |
| Free Cash Flow | $3.56B | - | - | - | $1.40B | - | - | - | $3.85B | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 71.9% | - | 66.4% | 71.8% | 70.0% | - | 70.9% | 70.9% | 66.7% | - |
| Operating margin | 26.6% | - | 12.1% | 31.7% | 28.0% | - | 26.5% | 27.6% | 22.7% | - |
| EBITDA margin | 27.8% | - | 13.3% | 32.9% | 29.3% | - | 27.8% | 28.9% | 24.2% | - |
| Net margin | 4.6% | - | 1.2% | 6.1% | 9.6% | - | 10.8% | 9.5% | 11.1% | - |
| Free cash flow margin | 23.8% | - | - | - | 10.5% | - | - | - | 31.3% | - |
| FCF / Net income | 5.13 | - | - | - | 1.09 | - | - | - | 2.81 | - |
| R&D / Revenue | 16.5% | - | 14.7% | 13.8% | 15.5% | - | 14.7% | 13.5% | 15.8% | - |
| SG&A / Revenue | 23.9% | - | 22.6% | 21.1% | 24.7% | - | 29.1% | 23.4% | 26.9% | - |
| Effective tax rate | 33.0% | - | 73.9% | 39.5% | 22.4% | - | 25.0% | 36.1% | 21.9% | - |
| Return on assets | 0.5% | - | 0.1% | 0.7% | 0.9% | - | 1.1% | 1.0% | 0.9% | - |
| Return on equity | -10.4% | - | -7.0% | -512.6% | 90.6% | - | 25.9% | 20.2% | 17.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.80 | 0.67 | 0.72 | 0.74 | 0.76 | 0.66 | 0.65 | 0.81 | 0.94 | 0.87 |
| Quick ratio | 0.68 | 0.56 | 0.60 | 0.61 | 0.64 | 0.55 | 0.54 | 0.71 | 0.83 | 0.76 |
| Cash ratio | 0.22 | 0.12 | 0.14 | 0.16 | 0.14 | 0.14 | 0.17 | 0.31 | 0.44 | 0.34 |
| Leverage | ||||||||||
| Debt / Equity | - | -19.73 | - | - | - | 20.10 | - | - | - | 5.72 |
| Debt / Assets | - | 0.48 | - | - | - | 0.49 | - | - | - | 0.44 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 5.6x | - | 2.6x | 6.6x | 5.3x | - | 5.3x | 5.5x | 4.2x | - |
| Equity multiplier | -20.50 | -40.97 | -50.68 | -749.63 | 95.89 | 40.65 | 23.78 | 20.94 | 18.59 | 13.00 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.12 | 0.11 | 0.10 | - | 0.10 | 0.10 | 0.08 | - |
| Inventory turnover | 0.84 | - | 1.07 | 0.88 | 0.88 | - | 0.95 | 1.00 | 0.96 | - |
| Days sales outstanding | 304d | - | 295d | 299d | 341d | - | 290d | 296d | 354d | - |
| Days inventory outstanding | 437d | - | 340d | 417d | 413d | - | 386d | 366d | 378d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 557.7x | - | 2315.4x | 357.0x | 291.0x | - | 224.4x | 222.8x | 236.5x | - |
| P / B | - | - | - | - | 261.5x | - | 58.0x | 44.8x | 40.3x | - |
| P / S | 25.7x | - | 26.0x | 21.3x | 27.8x | - | 24.2x | 21.0x | 26.2x | - |
| EV / EBITDA | 90.1x | - | 193.1x | 63.4x | 93.5x | - | 85.2x | 69.5x | 102.2x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 12.4% | - | 9.1% | 6.6% | 8.4% | - | 3.8% | 4.3% | 0.7% | - |
| Revenue CAGR (3y) | 7.1% | - | 2.1% | 1.9% | -0.5% | - | 0.3% | 1.2% | -1.8% | - |
| Revenue CAGR (5y) | 2.9% | - | 4.1% | 8.1% | 9.1% | - | 11.3% | 11.9% | 9.5% | - |
| Gross profit growth (YoY) | 15.4% | - | 2.2% | 8.0% | 13.7% | - | 37.7% | 6.6% | -0.3% | - |
| Operating income growth (YoY) | 6.9% | - | -50.3% | 22.4% | 33.4% | - | 68.0% | -11.4% | 1.1% | - |
| Net income growth (YoY) | -46.0% | - | -88.1% | -31.5% | -6.1% | - | -12.2% | -32.3% | 472.8% | - |
| EPS growth (YoY) | -45.8% | - | -88.6% | -32.5% | -6.5% | - | -12.0% | -32.5% | 492.3% | - |
| EPS CAGR (3y) | 44.2% | - | -64.4% | 0.6% | -34.0% | - | -20.9% | 22.4% | -27.1% | - |
| EPS CAGR (5y) | -27.8% | - | -40.0% | - | -18.6% | - | -6.9% | 9.5% | -14.1% | - |
| FCF growth (YoY) | 154.6% | - | - | - | -63.6% | - | - | - | -4.3% | - |
| FCF CAGR (5y) | -5.3% | - | - | - | -17.6% | - | - | - | 5.7% | - |
| Book value growth (YoY) | - | - | - | - | -82.3% | -67.9% | -50.1% | -47.3% | -39.7% | -40.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$47.21B totalSKYRIZI$15.20B · 32.2%
RINVOQ$5.94B · 12.6%
Vraylar$3.61B · 7.7%
Botox Therapeutic$3.15B · 6.7%
HUMIRA$3.06B · 6.5%
Other Products$2.63B · 5.6%
Imbruvica$2.05B · 4.3%
Creon$1.51B · 3.2%
Botox Cosmetic$1.50B · 3.2%
VENCLEXTA$1.31B · 2.8%
Ubrelvy$1.24B · 2.6%
Other Aesthetics$1.10B · 2.3%
Qulipta$906.00M · 1.9%
Linzess Constella$864.00M · 1.8%
MAVYRET$635.00M · 1.3%
Elahere$607.00M · 1.3%
Other Eye Care$588.00M · 1.2%
Juvederm Collection$385.00M · 0.8%
Other Neuroscience$192.00M · 0.4%
Lumigan Ganfort$189.00M · 0.4%
Vyalev$167.00M · 0.4%
Ozurdex$124.00M · 0.3%
Epkinly$90.00M · 0.2%
Duodopa$73.00M · 0.2%
Alphagan Combigan$53.00M · 0.1%
Other Oncology$33.00M · 0.1%
Geographic
$61.16B totalUS$46.60B · 76.2%
Other Countries$5.76B · 9.4%
DE$1.74B · 2.8%
JP$1.27B · 2.1%
CA$1.22B · 2.0%
CN$1.01B · 1.6%
FR$806.00M · 1.3%
GB$626.00M · 1.0%
ES$609.00M · 1.0%
IT$580.00M · 0.9%
BR$478.00M · 0.8%
AU$459.00M · 0.8%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AbbVie Inc. against the 5 most active filers in the same SIC group.
Dividends
$6.74/share trailing 12 months · +5.6% YoY
| Ex-date | Per share |
|---|---|
| Apr 15, 2026 | $1.7300 |
| Jan 16, 2026 | $1.7300 |
| Oct 15, 2025 | $1.6400 |
| Jul 15, 2025 | $1.6400 |
| Apr 15, 2025 | $1.6400 |
| Jan 15, 2025 | $1.6400 |
| Oct 15, 2024 | $1.5500 |
| Jul 15, 2024 | $1.5500 |
| Apr 12, 2024 | $1.5500 |
| Jan 12, 2024 | $1.5500 |
| Oct 12, 2023 | $1.4800 |
| Jul 13, 2023 | $1.4800 |
| Apr 13, 2023 | $1.4800 |
| Jan 12, 2023 | $1.4800 |
| Oct 13, 2022 | $1.4100 |
| Jul 14, 2022 | $1.4100 |
| Apr 13, 2022 | $1.4100 |
| Jan 13, 2022 | $1.4100 |
| Oct 14, 2021 | $1.3000 |
| Jul 14, 2021 | $1.3000 |
| Apr 14, 2021 | $1.3000 |
| Jan 14, 2021 | $1.3000 |
| Oct 14, 2020 | $1.1800 |
| Jul 14, 2020 | $1.1800 |